Cite
HARVARD Citation
Mesa, R. et al. (2017). The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF). British journal of haematology. pp. 76-85. [Online].